ESC · 2024

Ischemic Heart Disease (Chronic Coronary Syndromes) — Management Guideline

Source: ESC Guidelines for the Management of Chronic Coronary Syndromes, European Heart Journal, 2024

✓ Edition checked 3 Oct 2026 — ESC 2024 is the current edition as of this date.

Guideline: Strong Guideline: Conditional Guideline: Not recommended ClinicoQ pathway suggestion (not from the cited guideline)

Diagnosis

Diagnostic criteria Suspected chronic coronary syndrome is evaluated with a pretest probability assessment followed by noninvasive anatomic or functional imaging to confirm obstructive coronary artery disease.

⚠ Alarm features (investigate before diagnosing)

Rest angina or a crescendo pattern (suspected acute coronary syndrome — refer emergently)
Angina with hemodynamic instability or syncope
New heart failure symptoms
Significant ECG changes suggesting active ischemia

Initial workup

Test	When to order
Resting ECG	In all patients with suspected CCS at initial evaluation.
Noninvasive anatomic or functional imaging	First-line diagnostic testing, based on pretest likelihood of obstructive CAD.
Fasting lipid panel	At diagnosis, to guide lipid-lowering therapy intensity.
Deferral of further testing	Very low pretest likelihood (≤5%) of obstructive CAD.

Treatment

Lipid management (all patients)

1 High-intensity statin (e.g., atorvastatin) Strong (Guideline recommendation) — target LDL-C below 1.4 mmol/L (55 mg/dL) with ≥50% reduction from baseline

Dose: 40–80 mg once daily, maximum tolerated dose
Duration: Ongoing
Evidence level: High
Avoid if: Active liver disease; history of statin intolerance/myopathy
If no response ClinicoQ pathway: Add ezetimibe if the LDL-C target isn't met

2 Add ezetimibe Strong (Guideline recommendation), if LDL-C target not met on statin alone

Dose: 10 mg once daily
Duration: Ongoing
Evidence level: High
Avoid if: —
If no response ClinicoQ pathway: Add bempedoic acid or a PCSK9 inhibitor

Antianginal therapy

1 Beta-blocker and/or calcium channel blocker Strong (Guideline recommendation) — first-line for symptom control

Dose: e.g., bisoprolol 2.5–10 mg once daily, or amlodipine 5–10 mg once daily
Duration: Ongoing
Evidence level: High
Avoid if: Severe bradycardia, decompensated heart failure (beta-blockers); significant peripheral edema (CCBs)
If no response ClinicoQ pathway: Add a third antianginal agent only if symptoms remain uncontrolled and revascularization is unsuitable or pending

Antithrombotic therapy (secondary prevention)

1 Aspirin Strong (Guideline recommendation) — for prior MI, PCI, or significant obstructive CAD

Dose: 75–100 mg once daily
Duration: Long-term (lifelong after CABG)
Evidence level: High
Avoid if: Active bleeding; aspirin allergy
If no response: Clopidogrel 75 mg once daily is the guideline-recommended alternative (next step)

2 Clopidogrel (alternative to aspirin monotherapy) Strong (Guideline recommendation) — safe and effective alternative to aspirin monotherapy in patients with prior MI or remote PCI (Class I, level A)

Dose: 75 mg once daily
Duration: Long-term
Evidence level: High
Avoid if: Active bleeding; known clopidogrel hypersensitivity

⚠️ This is an educational summary of current international clinical practice guidelines and does not replace individualized clinical judgment. Final treatment decisions remain the responsibility of the treating physician.